Zepbound vs. Qsymia
Zepbound and Qsymia are both weight-loss drugs but differ significantly in their mechanisms. Zepbound, a GLP-1 and GIP receptor agonist, reduces appetite and slows gastric emptying, achieving substantial weight loss. Qsymia combines phentermine and topiramate to target appetite and reward pathways, also delivering significant weight loss. Zepbound’s side effects include nausea, while Qsymia may cause mood changes, insomnia, and stimulant-related risks. Zepbound’s cost is $1,125/month, while Qsymia averages $300/month. Neither drug faces current shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Phentermine suppresses appetite by stimulating the release of norepinephrine in the brain; topiramate enhances feelings of fullness and alters taste perceptions, reducing food intake.
Common Side Effects
Dry mouth, insomnia, constipation, dizziness, and tingling in hands or feet.
Serious Potential Side Effects
Increased heart rate, mood changes, suicidal thoughts, and memory/concentration difficulties, dependency and abuse of medication